These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 31515704)

  • 1. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
    Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Solomon JJ; Danoff SK; Woodhead FA; Hurwitz S; Maurer R; Glaspole I; Dellaripa PF; Gooptu B; Vassallo R; Cox PG; Flaherty KR; Adamali HI; Gibbons MA; Troy L; Forrest IA; Lasky JA; Spencer LG; Golden J; Scholand MB; Chaudhuri N; Perrella MA; Lynch DA; Chambers DC; Kolb M; Spino C; Raghu G; Goldberg HJ; Rosas IO;
    Lancet Respir Med; 2023 Jan; 11(1):87-96. PubMed ID: 36075242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
    Khanna D; Albera C; Fischer A; Khalidi N; Raghu G; Chung L; Chen D; Schiopu E; Tagliaferri M; Seibold JR; Gorina E
    J Rheumatol; 2016 Sep; 43(9):1672-9. PubMed ID: 27370878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease.
    Juge PA; Hayashi K; McDermott GC; Vanni KMM; Kowalski E; Qian G; Bade K; Saavedra A; Dieudé P; Dellaripa PF; Doyle TJ; Sparks JA
    Semin Arthritis Rheum; 2024 Feb; 64():152312. PubMed ID: 38056314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.
    Kelly CA; Saravanan V; Nisar M; Arthanari S; Woodhead FA; Price-Forbes AN; Dawson J; Sathi N; Ahmad Y; Koduri G; Young A;
    Rheumatology (Oxford); 2014 Sep; 53(9):1676-82. PubMed ID: 24758887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.
    Yang M; Wu Y; Liu X; Zhao C; Li T; Li T; Zhang X; Jiang H; Mao B; Liu W
    Respir Med; 2023 Sep; 216():107329. PubMed ID: 37315742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
    Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
    Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.
    Raimundo K; Solomon JJ; Olson AL; Kong AM; Cole AL; Fischer A; Swigris JJ
    J Rheumatol; 2019 Apr; 46(4):360-369. PubMed ID: 30442831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: Clinical features, biomarkers, and treatment options.
    Chen N; Diao CY; Gao J; Zhao DB
    Semin Arthritis Rheum; 2022 Aug; 55():152004. PubMed ID: 35472663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development.
    Jeong E; Hong H; Lee YA; Kim KS
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment.
    Pugashetti JV; Lee JS
    Semin Respir Crit Care Med; 2024 Jun; 45(3):329-341. PubMed ID: 38484788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
    Xie M; Zhu C; Ye Y
    BMC Pulm Med; 2023 Jul; 23(1):255. PubMed ID: 37434169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3).
    Wu C; Lin H; Zhang X
    Int Immunopharmacol; 2019 Sep; 74():105700. PubMed ID: 31228816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease.
    Lee KA; Kim BY; Kim SS; Cheon YH; Lee SI; Kim SH; Jung JH; Kim GT; Hur JW; Lee MS; Kim YS; Hong SJ; Park S; Kim HS
    Korean J Intern Med; 2024 Sep; 39(5):855-864. PubMed ID: 39252490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
    Maher TM; Tudor VA; Saunders P; Gibbons MA; Fletcher SV; Denton CP; Hoyles RK; Parfrey H; Renzoni EA; Kokosi M; Wells AU; Ashby D; Szigeti M; Molyneaux PL;
    Lancet Respir Med; 2023 Jan; 11(1):45-54. PubMed ID: 36375479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.
    Behr J; Neuser P; Prasse A; Kreuter M; Rabe K; Schade-Brittinger C; Wagner J; Günther A
    BMC Pulm Med; 2017 Sep; 17(1):122. PubMed ID: 28877715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
    Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
    Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.
    Liang M; Matteson EL; Abril A; Distler JHW
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221074457. PubMed ID: 35186127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.